<h4>Introduction</h4>3-Hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) inhibitors are widely used worldwide to treat dyslipidaemia and prevent cardiovascular events. This evidence concerns the gene HMGCR and inherited lipid metabolism disorder.